Aarti Drugs Limited Total Assets
Aarti Drugs Limited total assets. Based on the latest financial reports, Aarti Drugs Limited (AARTIDRUGS) holds total assets worth Rs28.15 Billion INR (≈ $304.46 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Aarti Drugs Limited (AARTIDRUGS) market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Aarti Drugs Limited (2006–2026)
Total assets of Aarti Drugs Limited from 2006 to 2026. This chart illustrates how Aarti Drugs Limited's total assets have evolved over time, based on quarterly financial data. See Aarti Drugs Limited (AARTIDRUGS) stock price for real-time trading data and today's change.
Aarti Drugs Limited - Asset Composition Analysis
Aarti Drugs Limited Total Assets Breakdown (March 2026)
Aarti Drugs Limited total assets breakdown as of March 2026. Aarti Drugs Limited's total assets of Rs28.15 Billion consist of 52.1% current assets and 47.9% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0.3% |
| Accounts Receivable | Rs8.31 Billion | 29.5% |
| Inventory | Rs4.91 Billion | 17.4% |
| Property, Plant & Equipment | Rs0.00 | 0.0% |
| Intangible Assets | Rs164.30 Million | 0.6% |
| Goodwill | Rs0.00 | 0.0% |
Asset Composition Trend (2006–2026)
This chart illustrates how Aarti Drugs Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore AARTIDRUGS working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Aarti Drugs Limited's current assets represent 52.1% of total assets in 2026, an increase from 49.1% in 2006.
- Cash Position: Cash and equivalents constituted 0.3% of total assets in 2026, down from 0.5% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 6.0% in 2006.
- Asset Diversification: The largest asset category is accounts receivable at 29.5% of total assets.
Aarti Drugs Limited Competitors by Total Assets
Key competitors of Aarti Drugs Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
|
China | CN¥9.54 Billion |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211
|
China | CN¥6.44 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Bide Pharmatech Co. Ltd. A
SHG:688073
|
China | CN¥2.54 Billion |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976
|
China | CN¥4.69 Billion |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
|
China | CN¥2.26 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥25.73 Billion |
Aarti Drugs Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.59 | 1.60 | 1.78 |
| Quick Ratio | 1.06 | 1.03 | 1.08 |
| Cash Ratio | 0.00 | 0.01 | 0.00 |
| Working Capital | Rs5.46 Billion | Rs5.01 Billion | Rs4.61 Billion |
Aarti Drugs Limited - Advanced Valuation Insights
This section examines the relationship between Aarti Drugs Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.53 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | 9.3% |
| Total Assets | Rs28.15 Billion |
| Market Capitalization | $460.26 Million USD |
Valuation Analysis
Below Book Valuation: The market values Aarti Drugs Limited's assets below their book value (0.02x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Aarti Drugs Limited's assets grew by 9.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Aarti Drugs Limited (2006–2026)
The table below shows the annual total assets of Aarti Drugs Limited from 2006 to 2026.
| Year | Total Assets | Change |
|---|---|---|
| 2026-03-31 | Rs28.15 Billion ≈ $304.46 Million |
+9.34% |
| 2025-03-31 | Rs25.75 Billion ≈ $278.44 Million |
+5.85% |
| 2024-03-31 | Rs24.32 Billion ≈ $263.05 Million |
+0.45% |
| 2023-03-31 | Rs24.21 Billion ≈ $261.87 Million |
+9.67% |
| 2022-03-31 | Rs22.08 Billion ≈ $238.78 Million |
+25.02% |
| 2021-03-31 | Rs17.66 Billion ≈ $190.99 Million |
+12.02% |
| 2020-03-31 | Rs15.77 Billion ≈ $170.49 Million |
+7.77% |
| 2019-03-31 | Rs14.63 Billion ≈ $158.20 Million |
+5.40% |
| 2018-03-31 | Rs13.88 Billion ≈ $150.10 Million |
+17.88% |
| 2017-03-31 | Rs11.77 Billion ≈ $127.33 Million |
+6.82% |
| 2016-03-31 | Rs11.02 Billion ≈ $119.20 Million |
+10.01% |
| 2015-03-31 | Rs10.02 Billion ≈ $108.36 Million |
+17.91% |
| 2014-03-31 | Rs8.50 Billion ≈ $91.90 Million |
+18.07% |
| 2013-03-31 | Rs7.20 Billion ≈ $77.83 Million |
+17.48% |
| 2012-03-31 | Rs6.13 Billion ≈ $66.25 Million |
+17.03% |
| 2011-03-31 | Rs5.23 Billion ≈ $56.61 Million |
+24.91% |
| 2010-03-31 | Rs4.19 Billion ≈ $45.32 Million |
+3.93% |
| 2009-03-31 | Rs4.03 Billion ≈ $43.61 Million |
-3.22% |
| 2008-03-31 | Rs4.17 Billion ≈ $45.06 Million |
+13.74% |
| 2007-03-31 | Rs3.66 Billion ≈ $39.62 Million |
-0.31% |
| 2006-03-31 | Rs3.67 Billion ≈ $39.74 Million |
-- |
About Aarti Drugs Limited
Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enro… Read more